BioAge Labs, Inc.

BioAge Labs reported a net loss of $(48.35) million for the first six months of 2026, an increase from $(34.49) million in the same period last year, driven by higher research and development expenses. Collaboration revenue saw an increase to $5.22 million. The company significantly bolstered its financial position through a public offering in January 2026, raising $107.4 million, and an at-the-market program, adding $32.7 million, ensuring liquidity for at least the next year.

BioAge Labs reported a net loss of $26.1 million, or $0.58 per share, for the second quarter of 2026, compared to a net loss of $21.6 million, or $0.60 per share, in the same period last year. Research and development expenses increased to $24.4 million, primarily due to advancements in the BGE-102 program. The company announced the dosing of the first participant in its QUELL-CV Phase 2 trial for BGE-102 and plans to initiate the QUELL-DME Phase 1b/2a trial in mid-2026. BioAge Labs maintains a strong financial position with $381.3 million in cash, cash equivalents, and marketable securities, projected to fund operations through 2029.

BioAge Labs announced that the first participant was dosed in QUELL-CV, a Phase 2 trial for its lead candidate BGE-102, with topline data expected in H2 2026. The company also plans to initiate the QUELL-DME Phase 1b/2a trial for BGE-102 in diabetic macular edema in mid-2026. For Q2 2026, BioAge reported a net loss of $26.1 million and R&D expenses of $24.4 million. The company maintains a strong cash position of $381.3 million, providing a runway through 2029.

BioAge Labs announced the dosing of the first participant in QUELL-CV, a Phase 2 clinical trial for BGE-102, its lead product candidate for cardiovascular risk reduction. The trial is a randomized, double-blind, placebo-controlled, dose-ranging study evaluating three once-daily oral doses in approximately 160 adults with elevated systemic inflammation and cardiovascular risk factors. The primary endpoint is the percent change in high-sensitivity C-reactive protein (hsCRP), with topline data expected in the second half of 2026. This builds on positive Phase 1 results where BGE-102 achieved significant hsCRP reductions and was well tolerated. BioAge also plans to initiate a Phase 1b/2a trial for BGE-102 in diabetic macular edema in mid-2026.

BioAge Labs, Inc. announced its participation in two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York and the Goldman Sachs Global Healthcare Conference in Miami Beach. CFO Dov Goldstein and Chief Strategy Officer BJ Sullivan will represent the company, participating in fireside chats and one-on-one meetings. The company, a clinical-stage biotechnology firm, is developing therapeutic candidates for metabolic diseases, with its lead candidate BGE-102 targeting cardiovascular risk and retinal diseases.

BioAge Labs reported its first quarter 2026 financial results, including a net loss of $22.3 million and collaboration revenue of $2.8 million. The company announced positive topline Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory biomarkers. BioAge Labs plans to initiate two Phase 2 proof-of-concept trials for BGE-102 in cardiovascular risk and diabetic macular edema by mid-2026, and completed an upsized public offering raising $132.3 million, extending its cash runway through 2029.

BioAge Labs reported a net loss of $(22.25) million for Q1 2026, an increase from $(12.93) million in Q1 2025, primarily due to higher research and development expenses. Collaboration revenue increased to $2.77 million for the quarter. The company significantly strengthened its liquidity by raising $123.6 million in net proceeds from an underwritten public offering in January and February 2026, bringing total cash, cash equivalents, and marketable securities to $384.9 million as of March 31, 2026.

BioAge Labs announced it will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for its lead product candidate, BGE-102. The event will focus on the NLRP3 inflammasome inhibitor's therapeutic rationale for atherosclerotic cardiovascular disease (ASCVD) and retinal disease. BioAge management will be joined by four leading experts to discuss NLRP3 biology and the diseases BGE-102 aims to treat. The company anticipates Phase 2 cardiovascular risk data in H2 2026 and Phase 1b/2a diabetic macular edema data in mid-2027.

BioAge Labs reported positive Phase 1 clinical trial results for BGE-102, an NLRP3 inhibitor. Both 60 mg and 120 mg once-daily doses achieved at least 85% median hsCRP reductions in participants with obesity and elevated inflammation, demonstrating potential best-in-class efficacy and a favorable tolerability profile. Based on these results, BioAge plans to initiate a Phase 2 cardiovascular risk trial and a Phase 1b/2a diabetic macular edema trial in mid-2026, with data anticipated by end of 2026 and mid-2027, respectively.

BioAge Labs, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference from April 13-16, 2026. CEO Kristen Fortney will host a fireside chat on April 16, 3:00 PM EDT. She, along with the CFO and Chief Strategy Officer, will also hold one-on-one meetings. The event offers investors insights into the company's clinical-stage programs, including BGE-102 for cardiovascular and retinal diseases, and APJ agonists for obesity.